ArticleFrontiers in oncology2026
Clinical and CT/MRI features of hepatic AL amyloidosis: preliminary experience in 10 cases.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: To identify the key clinical and imaging clues on computed tomography (CT) and magnetic resonance imaging (MRI) that can suggest the diagnosis of hepatic AL amyloidosis, thereby improving diagnostic accuracy and timely recognition among peers. Methods: We retrospectively analyzed the clinical, CT, and MRI findings of 10 patients with confirmed hepatic AL amyloidosis. Results: The predominant clinical manifestations included hepatomegaly (10/10, 100%), abdominal distension (9/10, 90%), fatigue (4/10, 40%), and weight loss (3/10, 30%). Laboratory findings showed markedly elevated alkaline phosphatase (ALP) and gamma-glutamyl transferase (GGT) (10/10, 100%), with normal or mildly elevated transaminases; hypoalbuminemia was present in all patients (10/10, 100%). CT imaging demonstrated diffuse hepatomegaly with decreased hepatic attenuation in all 8 patients who underwent CT. MRI (6 patients) showed marked hepatomegaly with smooth margins, mildly and uniformly increased T2WI signal, along with vascular rarefaction. Contrast-enhanced CT/MRI revealed delayed enhancement. Additionally, poor visualization or stenosis of the main hepatic veins and periportal edema were also observed in all cases (10/10, 100%). MRCP was performed in 5 patients, and none showed evidence of biliary obstruction. Splenic hypoperfusion was observed in 7 patients, and renal hypoperfusion in 2 patients. Conclusions: Despite its low incidence, hepatic AL amyloidosis should be suspected in patients presenting with unexplained hepatomegaly, markedly elevated ALP/GGT with relatively preserved transaminases, and specific imaging findings such as delayed enhancement, poor visualization or stenosis of the main hepatic veins, and periportal edema. Recognition of these clues, along with extrahepatic findings such as splenic or renal hypoperfusion, can significantly improve diagnostic accuracy and timely recognition of this disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.